Aigen Investment Management LP acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 13,232 shares of the medical research company’s stock, valued at approximately $163,000. Other hedge funds also recently added to or reduced their […]
William Blair reaffirmed their outperform rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report report published on Wednesday, RTT News reports. William Blair also issued estimates for NeoGenomics’ Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.02 […]
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the transaction, the general counsel now owns 34,866 shares of […]
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript February 20, 2024 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.01. NEO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the NeoGenomics Fourth Quarter and Full […]